BiotechTV – From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment-resistant depression to improve on the risk profile seen today with esketamine

An interview exploring the unmet need in treatment-resistant depression and FundaMental Pharma’s approach to developing next-generation therapies for patients.